



Psoriatic Arthritis (US)

OVERVIEW

The US Psoriatic Arthritis (PsA) market has been experiencing large-scale change as rheumatologists continue adoption of alternate MOA biologics. Uptake of Novartis' Cosentyx and BMS' Orencia will challenge the leading TNF-inhibitors, while a pipeline ripe with line-extensions and new biologics is due to bring further disruption.

The **RealTime Dynamix™: Psoriatic Arthritis (US)** report series provides a detailed and timely look at current and future trends in the PsA market, and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the rheumatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

SAMPLE & METHODOLOGY

The report is based on an online survey of ~100 US rheumatologists and is fielded on a quarterly basis. Respondents are recruited from the Spherix Network, a proprietary group of rheumatologists in clinical practice meeting quality screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output.

KEY QUESTIONS ANSWERED

- How is Otezla holding ground against the increasingly competitive biologics?
- Do rheumatologists differentiate among TNF inhibitors and if so, how?
- How has the launch of Cosentyx impacted the PsA market and Stelara use in particular?
- How will the introduction of Orencia impact TNF cycling and the newer alternate biologics in PsA?
- Will Taltz expand IL-17 segment or dampen Costentyx growth?
- Will rhematologists follow in the footsteps of dermatologists for the adoption of Taltz?
- Will the lack of PsO indication limit use of Pfizer's Xeljanz and Janssen's Simponia Aria in PsA, if approved?
- How will biosimilars (Inflectra, Erelzi) impact the management of PsA?
- What role are patients and payers playing in the biologic brand choice?

Products Profiled

Commercial Products

*AbbVie (Humira), Amgen (Enbrel), BMS (Orencia), Celgene (Otezla), Janssen (Remicade, Simponi, Stelara), Novartis (Cosentyx), UCB Pharma (Cimzia)
Biosimilars: Pfizer (Inflectra), Merck (Renflexis)*

Pipeline Agents

Eli Lilly (Taltz), Pfizer (Xeljanz), Janssen (guselkumab)

Key Dates

- Q1 March
- Q2 July
- Q3 September
- Q4 December

Note: a three day embargo is placed on delivery to non-manufacturers allowing clients time to digest the findings before public dissemination

Deliverables

- PowerPoint report
- Frequency Tables & Summary Statistics
- On-site presentation
- Proprietary questions (for purchasers of the annual series)

Related Reports

- RealTime Dynamix™: Psoriatic Arthritis EU
- RealWorld Dynamix™: Biologic/Otezla Switching in Psoriatic Arthritis US
- RealTime Dynamix™: Psoriasis US
- RealWorld Dynamix™: Biologic/Otezla Switching in Psoriasis US
- RealTime Dynamix™: Rheumatoid Arthritis US
- RealTime Dynamix™: Rheumatoid Arthritis EU

Pricing

- \$19,500 single quarterly wave
- \$69,500 annual series of four reports